MINIMIZING PROLIFERATIVE VITREORETINOPATHY REACTION IN RHEGMATOGENOUS RETINAL DETACHMENT: IS THERE A ROLE OF PREOPERATIVE ANTI-INFLAMMATORY?

Pastor JC, De La Rúa ER, Martín F. Proliferative vitreoretinopathy: Risk factors and pathobiology. Prog Retin Eye Res. 2002;21:127–44.

Tosi GM, Marigliani D, Romeo N, Toti P. Disease pathways in proliferative vitreoretinopathy: an ongoing challenge. J Cell Physiol. 2014;22:1577–83.

Pastor-Idoate S, Delgado-Tirado S, Pastor JC, Di Lauro S, Rojas J, Gonzalez- Buendia L, dkk. Proliferative vitreoretinopathy: A new concept of disease pathogenesis and practical consequences.Prog Retin Eye Res. 2015;51:125– 55.

Moysidis SN, Thanos A, Vavvas DG. Mechanisms of inflammation in proliferative vitreoretinopathy: From bench to bedside. Mediators Inflamm. 2012;2012:815937

Radi ZA, Render JA. The pathophysiologic role of cyclo-oxygenases in the eye. J Ocul Pharmacol Ther. 2008;2:141–51.

Diana N, Victor AA, Elvioza E, Prihartono J. Comparison of Topical nepafenac 0.1 % and prednisolone acetate 1% as an anti- inflammatory after vitrectomy in rhegmatogenous retinal detachment. eJournal Kedokt Indones. 2019;7;1–6.

Djatikusumo A, Victor AA, La Distia R et al. Nepafenac 0,1% Effect on Vitreous Inflammatory Biomarkers in Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy. 2023.

Pollack A, Staurenghi G, Sager D, Mukesh B, Reiser H, Singh RP . Prospective randomised clinical trial to evaluate the safety and efficacy of nepafenac 0.1% treatment for the prevention of macular oedema associated with cataract surgery in patients with diabetic retinopathy. Br J Ophthalmol. 2017;101:423–7.

Pastor-Idoate S, Delgado-Tirado S, Pastor JC, Di Lauro S, Rojas J, Gonzalez- Buendia L, dkk. Proliferative vitreoretinopathy: A new concept of disease pathogenesis and practical consequences. Prog Retin Eye Res. 2015;51:125– 55.

Carpineto P, Licata AM, Ciancaglini M. Proliferative Vitreoretinopathy: A Reappraisal. J Clin Med. 2023 Aug 14;12(16):5287

Liu F, Meyer CH, Mennel S, Hoerle S, Kroll P . Visual recovery after scleral buckling surgery in macula-off rhegmatogenous retinal detachment. Ophthalmologica. 2006;220:174–180.

Kahler CM, Kieselbach GF, Reinisch N, Troger J, Gttinger. Fibroblast growth- promoting activity in proliferative vitreoretinopathy: antagonism by acetylsalicylic acid. Eur J Pharmacol. 1994;261–9.

Tikhonovich M V., Erdiakov AK, Gavrilova SA. Nonsteroid anti- inflammatory therapy suppresses the development of proliferative vitreoretinopathy more effectively than a steroid one. Int Ophthalmol. 2018;38:1365–78.

Widjaja SA, Hiratsuka Y, Ono K, Firmansjah M, Sasono W, Murakami A. The impact of travel distance to delayed presentation and follow-up attendance of retinal detachment cases in Surabaya, Indonesia. Juntendo Medical Journal. 2022;68(1):36-43.